Don’t miss – Page 203 – Endpoints News

SIGN UP

Celgene racks up third Otezla approval, heating up talks about who Bristol-Myers will sell to

4 years ago

In another disappointment for investors, FDA slaps down Biohaven’s revised version of an old ALS drug

4 years ago

On a hot streak, Novartis execs run the odds on their two most important PhIII readouts. Which is 0.01% more likely to succeed?

4 years ago

Medicxi is rolling out its biggest fund ever to back Europe's top 'scientists with strange ideas'

4 years ago

After a decade, ViiV CSO John Pottage says it's time to step down — and he's handing the job to longtime colleague Kim Smith

4 years ago

On a global romp, Boehringer BD team picks up its third R&D alliance for July — this time focused on IPF with $50M upfront

4 years ago

Backed by some of the biggest names in biotech, Norbert Bischofberger gets his megaround for platform tech out of MIT

4 years ago

With looming ‘apocalypse of drug resistance,’ Merck’s combination antibiotic scores FDA approval on two fronts

4 years ago

The $1.1M goodbye: Gilead CSO John McHutchison is out as Daniel O’Day shakes up the senior team

4 years ago

Going inside cells, Sung Joo Lee has sketched some big goals for his small — but global — team of drug hunters

4 years ago

Astellas buys into Frequency's regenerative med strategy with a $625M alliance on hearing loss

4 years ago

Part club, part guide, part landlord: Arie Belldegrun is blueprinting a string of bespoke biotech complexes in global boomtowns — starting with Boston

4 years ago

Takeda's translational cell therapy group revs up for a race to the clinic with off-the-shelf CAR-T

4 years ago

Boehringer buys Swiss biotech in its latest M&A deal, going the next-gen cancer vaccine route

4 years ago

AbbVie beefs up the oncology pipeline, bagging an upstart STING player with its own unique approach

4 years ago

Gilead unleashes a $5B late-stage cash alliance with Galapagos — laying out O'Day's R&D strategy

4 years ago

Amgen, Novartis scrap Alzheimer's studies — is BACE finally dead or will Biogen and Eisai carry on?

4 years ago

Alnylam’s Maraganore switches ‘perhaps the best CFO in mid-cap biotech’ with Shire vet Jeff Poulton

4 years ago

Analysis: In most of the Big Pharma world, R&D spending towers over revenue from new drugs. Guess who beat the odds

4 years ago

White House changes course to kill rebate reform

4 years ago

GlaxoSmithKline recruits a new coach and top player for their AI/ML team out of Genentech and MIT

4 years ago

The FDA's Janet Woodcock talks about some big changes she's pushing for in drug development, and agency reviews

4 years ago

KRAS G12C is the hot new play in cancer R&D, and Novartis jumps in with a combo deal

4 years ago

Ex-Genentech star and 23andMe vet Richard Scheller jumps to newly public unicorn biotech BridgeBio as ‘chairman of R&D’

4 years ago

First page Previous page 200 201 202203204 205 206 Next page Last page